the early and late changes in these parameters have been observed and compared with standard clinical and biochemical assessments of disease activity in 90 patients with active ra , randomly assigned to receive either sodium aurothiomalate , auranofin , or auranofin placebo .
C0003873
ra
C0004320
auranofin